MAPT and oculocutaneous albinism type 1: The inclusion of plasma GFAP as a marker of inflammation in most recent revisions of the amyloid-tau-neurodegeneration (ATN) profile classification is an initial step for further understanding the complex interplay of the response of the brain to pathological deposits.